Multimedia

Don’t miss early joint involvement in psoriasis


 

EXPERT ANALYSIS FROM SDEF HAWAII DERMATOLOGY SEMINAR

Check for joint tenderness and swelling routinely in your psoriasis patients, to detect psoriatic joint disease at an early stage, advised Alan Menter, MD.

About a third of patients with psoriasis will go on to develop joint involvement, and about half of those will go on to develop permanent joint destruction “if left untreated,” he noted. But early joint involvement has to be caught first, and dermatologists aren’t doing a very good job at early detection, according to Dr. Menter, clinical professor of dermatology at the University of Texas, Dallas.

The consequences, including arthritis mutilans, can be devastating. “It’s vitally important for us to prevent any permanent joint disease by” picking it up early, he said. “Our job as dermatologists is to diagnose it early.”

It’s not hard to do, just a few extra questions and a few extra steps on the physical exam, which takes a minute or two during each visit with psoriasis patients, are needed, he said.

Dr. Menter reviewed questions to ask patients, and explained how to examine patients for joint involvement and alter treatment when it’s found, in an interview at the Hawaii Dermatology Seminar provided by Global Academy for Medical Education/Skin Disease Education Foundation.

SDEF/Global Academy for Medical Education and this news organization are owned by the same parent company.

Recommended Reading

Positive results reported for ixekizumab versus adalimumab in PsA
MDedge Rheumatology
Back pain criteria perform well in patients with active axial psoriatic arthritis
MDedge Rheumatology
CONDOR trial: Most psoriasis patients can be downshifted to reduced-dose biologics
MDedge Rheumatology
Longterm maintenance of PASI 75 responses observed with tildrakizumab
MDedge Rheumatology
Brodalumab raced past ustekinumab to PASI 100
MDedge Rheumatology
Psoriatic arthritis eludes early diagnosis
MDedge Rheumatology
Comorbidities may cut effectiveness of psoriasis biologics
MDedge Rheumatology
Guselkumab tops secukinumab over 48 weeks for plaque psoriasis
MDedge Rheumatology
Different disease features found with family history of psoriasis versus PsA
MDedge Rheumatology
Biologics curb coronary artery plaques in severe psoriasis
MDedge Rheumatology